ATE361101T1 - Nahrungszusammensetzung die unverdauliche oligosaccharide enthält - Google Patents

Nahrungszusammensetzung die unverdauliche oligosaccharide enthält

Info

Publication number
ATE361101T1
ATE361101T1 AT04077394T AT04077394T ATE361101T1 AT E361101 T1 ATE361101 T1 AT E361101T1 AT 04077394 T AT04077394 T AT 04077394T AT 04077394 T AT04077394 T AT 04077394T AT E361101 T1 ATE361101 T1 AT E361101T1
Authority
AT
Austria
Prior art keywords
composition containing
food composition
containing indigestible
indigestible oligosaccharides
composition
Prior art date
Application number
AT04077394T
Other languages
English (en)
Inventor
Guenther Boehm
Rabet Laura M
Bernd Stahl
Johan Garssen
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928473&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE361101(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutricia Nv filed Critical Nutricia Nv
Application granted granted Critical
Publication of ATE361101T1 publication Critical patent/ATE361101T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21Addition of substantially indigestible substances, e.g. dietary fibres
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733Fructosans, e.g. inulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/51Bifidobacterium
    • A23V2400/519Breve

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pediatric Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04077394T 2004-08-24 2004-08-24 Nahrungszusammensetzung die unverdauliche oligosaccharide enthält ATE361101T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04077394.7A EP1629850B2 (de) 2004-08-24 2004-08-24 Nahrungszusammensetzung die unverdauliche Transgalaktooligosaccharide sowie verdauliche Galaktose-Saccharide enthält

Publications (1)

Publication Number Publication Date
ATE361101T1 true ATE361101T1 (de) 2007-05-15

Family

ID=34928473

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04077394T ATE361101T1 (de) 2004-08-24 2004-08-24 Nahrungszusammensetzung die unverdauliche oligosaccharide enthält

Country Status (19)

Country Link
US (4) US8277835B2 (de)
EP (5) EP1629850B2 (de)
JP (1) JP5142717B2 (de)
CN (2) CN101043904B (de)
AT (1) ATE361101T1 (de)
AU (2) AU2005275577B2 (de)
BR (1) BRPI0514536A (de)
CA (2) CA2577926C (de)
DE (1) DE602004006258T3 (de)
DK (2) DK1629850T4 (de)
ES (3) ES2286558T5 (de)
NZ (1) NZ553390A (de)
PL (2) PL1629850T5 (de)
PT (2) PT1629850E (de)
RU (2) RU2385714C2 (de)
SG (1) SG170119A1 (de)
TR (1) TR201820868T4 (de)
UA (1) UA89791C2 (de)
WO (2) WO2006022542A1 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
ES2286558T5 (es) 2004-08-24 2013-10-15 N.V. Nutricia Composición nutritiva que comprende transgalactooligosacáridos indigeribles y sacáridos de galactosa digeribles
US20060229366A1 (en) * 2005-04-07 2006-10-12 Lifschitz Carlos H Method for preventing or treating respiratory infections in infants
EP1714660A1 (de) * 2005-04-21 2006-10-25 N.V. Nutricia Uronsäure und Probiotika
EP1776877A1 (de) 2005-10-21 2007-04-25 N.V. Nutricia Methode zur Förderung der Darmflora
US20070202215A1 (en) * 2006-02-28 2007-08-30 Zahramehran Salari Lak Dietary nutritional supplements for persons consuming alcohol products
US9005682B2 (en) 2006-03-07 2015-04-14 Nestec S.A. Synbiotic mixture
WO2008054193A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Nutritional products that comprise saccharide oligomers
NL1032840C2 (nl) * 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
WO2008153377A1 (en) * 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
WO2009063226A2 (en) * 2007-11-12 2009-05-22 Karolinska Institutet Innovations Ab Methods relating to breathing disorders
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
CA2718222A1 (en) 2008-03-14 2009-09-17 Nestec S.A. Synbiotic mixture
EP2130440A1 (de) * 2008-06-06 2009-12-09 N.V. Nutricia Hemmen des E. Sakazakii-Wachstums
WO2009157759A1 (en) * 2008-06-23 2009-12-30 N.V. Nutricia Nutritional composition for improving the mammalian immune system
WO2010002241A1 (en) * 2008-06-30 2010-01-07 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
US20100043075A1 (en) * 2008-08-13 2010-02-18 Autodesk, Inc. Licensing management utility
WO2010068086A1 (en) * 2008-12-11 2010-06-17 N.V. Nutricia Nutritional compositions with large lipid globule size
US8785160B2 (en) 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
SG2014014435A (en) 2009-02-24 2014-07-30 Ritter Pharmaceuticals Inc Prebiotic formulations and methods of use
CA2761444C (en) * 2009-05-11 2018-04-24 Nestec S.A. Lactobacillus johnsonii la1 ncc533 (cncm i-1225) and immune disorders
US20120178674A1 (en) 2009-07-15 2012-07-12 N.V. Nutricia Mixture of non-digestible oligosaccharides for stimulating the immune system
EP4197542A1 (de) 2009-07-15 2023-06-21 N.V. Nutricia Fucosyllaktose als muttermilchidentisches unverdauliches oligosaccharid zur verwendung bei der verbesserung der impfreaktion
EP2322169A1 (de) * 2009-11-13 2011-05-18 Laboratorios Casen-Fleet, S.L. Zusammensetzung enthaltend ein DHA-Öl für den Einsatz in der Behandlung zystischer Fibrose
NL2004099C2 (en) * 2010-01-15 2011-07-18 Friesland Brands Bv Milk derived antigen specific antibodies for inducing an adaptive immune response, methods of preparation and uses thereof.
BE1019290A5 (nl) 2010-04-14 2012-05-08 Nutrition Sciences Nv Sa Voedingsupplement omvattende oligosachariden en middellange keten vetzuren.
EP2465509A1 (de) * 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharid Zusammensetzung zur Behandlung von akuten Atemwegsinfektionen
EP2643017B1 (de) 2010-11-23 2019-05-22 Pantheryx, Inc. Behandlungszusammensetzungen und -verfahren mit undifferenzierten oder gemischten klinischen anwendungen aus einem breiten spektrum
WO2012087113A1 (en) 2010-12-24 2012-06-28 N.V. Nutricia Improved nutritional tablet
EP2658400A2 (de) 2010-12-31 2013-11-06 Abbott Laboratories Nahrungsformulierungen mit menschlichen milcholigosacchariden und antioxidantien und verwendungen davon
US8802650B2 (en) 2010-12-31 2014-08-12 Abbott Laboratories Methods of using human milk oligosaccharides for improving airway respiratory health
WO2012092153A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
EP2658548B1 (de) 2010-12-31 2018-02-21 Abbott Laboratories Oligosaccharide aus muttermilch zur modulierung von entzündungen
JP5900792B2 (ja) * 2011-02-21 2016-04-06 国立大学法人信州大学 フェルラ酸結合型糖質の製造方法
US8563611B2 (en) * 2011-03-17 2013-10-22 Women's & Children's Health Research Institute Methods and compositions for promoting the respiratory development of an infant
RU2464796C1 (ru) * 2011-06-01 2012-10-27 Государственное образовательное учреждение высшего профессионального образования Воронежская государственная технологическая академия (ГОУ ВПО ВГТА) Способ получения фукозосодержащей функциональной добавки из молочной сыворотки
RU2630299C2 (ru) 2011-06-20 2017-09-06 Г.Дж. Хайнц Компани Брэндс ЛЛК Композиции, способ и наборы для стимулирования мукозальной иммунной системы
WO2012177118A1 (en) * 2011-06-22 2012-12-27 N.V. Nutricia Method for reducing the occurrence of infection in young children
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
NL2007268C2 (en) 2011-08-16 2013-02-19 Friesland Brands Bv Nutritional compositions comprising human milk oligosaccharides and uses thereof.
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
RU2471496C1 (ru) * 2011-11-17 2013-01-10 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии Сибирского отделения РАМН Средства, повышающие противоопухолевую и антиметастатическую активность цитостатических препаратов
WO2014100126A1 (en) 2012-12-18 2014-06-26 Abbott Laboratories Human milk oligosaccharides to ameliorate symptoms of stress
ITMI20122270A1 (it) * 2012-12-31 2014-07-01 Giovanni Mogna Terapia di supporto ai trattamenti di chemioterapia per i tumori, per la sindrome da immunodeficienza acquisita e per le leucemie.
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CA2911496C (en) 2013-05-10 2023-08-22 H.J. Heinz Company Brands Llc Probiotics and methods of use
SE537951C2 (sv) * 2013-07-01 2015-12-01 Hero Ag Profylaktisk användning av modersmjölksersättning mot otit
AU2014350144B2 (en) 2013-11-15 2019-11-21 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of URT infections in infants or young children at risk
WO2016042831A1 (ja) * 2014-09-18 2016-03-24 協和化学工業株式会社 大腸の検査または手術のための処置用製剤
DK3065748T3 (da) 2014-12-23 2018-01-29 4D Pharma Res Ltd En bacteroides thetaiotaomicron stamme og dens anvendelse til reduktion af inflammation
NO3193901T3 (de) 2014-12-23 2018-09-01
SI3650033T1 (sl) 2015-06-15 2022-05-31 4D Pharma Research Limited Sestavki, ki obsegajo bakterijske seve
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3636272A1 (de) 2015-06-15 2020-04-15 4D Pharma Research Limited Zusammensetzungen mit bakterienstämmen
TW202222339A (zh) 2015-06-15 2022-06-16 英商4D製藥研究有限公司 包含細菌菌株之組合物
CN107921058B (zh) * 2015-08-04 2021-04-16 南方糖业股份公司 菊糖对鼻窦炎的预防作用
MX2018006240A (es) 2015-11-20 2018-08-01 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas.
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
PT3389404T (pt) 2015-12-15 2020-01-14 Nestle Sa Mistura de hmos
WO2017114901A1 (en) * 2015-12-29 2017-07-06 N.V. Nutricia Nutritional formula with non-digestible oligosaccharides and non-replicating lactic acid producing bacteria
EP3207933A1 (de) * 2016-02-17 2017-08-23 Proponent Biotech GmbH Verwendungen von polyfructanen
SI3313423T1 (sl) 2016-03-04 2019-07-31 4D Pharma Plc Sestavki, ki vsebujejo bakterijske seve Blautia za zdravljenje visceralne preobčutljivosti
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TW201821093A (zh) 2016-07-13 2018-06-16 英商4D製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
DK3630136T3 (da) 2017-05-22 2021-05-25 4D Pharma Res Ltd Sammensætninger, der omfatter bakteriestammer
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
LT3638271T (lt) 2017-06-14 2021-01-11 4D Pharma Research Limited Kompozicijos, apimančios bakterines padermes
EP4104843A1 (de) 2017-06-14 2022-12-21 4D Pharma Research Limited Zusammensetzungen mit bakterienstämmen
WO2019031961A1 (en) 2017-08-11 2019-02-14 N.V. Nutricia OLIGOSACCHARIDE OF HUMAN MILK TO IMPROVE PHYSICAL IMMUNE CONDITION
US20210161924A1 (en) * 2018-06-19 2021-06-03 Evolve Biosystems, Inc. Novel oligosaccharides for use in prebiotic applications
CN108888762A (zh) * 2018-08-15 2018-11-27 福建傲农生物科技集团股份有限公司 一种含益生菌代谢产物的组合物
CN114144078B (zh) * 2019-07-23 2024-06-11 菲仕兰坎皮纳荷兰公司 包含乳脂肪和免疫球蛋白的营养组合物
IL297038A (en) * 2020-04-06 2022-12-01 Abbott Lab Dietary formulations for modulation of airway-induced cytokines
EP4142742A4 (de) * 2020-04-30 2024-05-29 Dsm Nutritional Products Llc Oligosaccharidzusammensetzungen und verfahren zur verwendung davon zur behandlung von virusinfektionen
US11324766B2 (en) 2020-05-13 2022-05-10 Glycosyn LLC 2'-fucosyllactose for the prevention and treatment of coronavirus-induced inflammation
JP2023526273A (ja) * 2020-05-13 2023-06-21 グリコシン リミテッド ライアビリティー カンパニー コロナウイルス感染の防止のためのフコシル化オリゴ糖
EP4370104A1 (de) * 2021-07-16 2024-05-22 Purdue Research Foundation Präbiotische zusammensetzung und verfahren zur verwendung zur verbesserung der magen-darm-gesundheit bei patienten mit dysbiose und undichtem darm

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH627079A5 (en) 1977-04-15 1981-12-31 Nestle Sa Process for preparing a protein concentrate containing immunological factors of milk origin
SE8301609D0 (sv) 1983-03-23 1983-03-23 Svenska Sockerfabriks Ab Forening och komposition for terapeutisk eller diagnostisk anvendning jemte forfarande for terapeutisk behandling
US4661345A (en) 1985-02-26 1987-04-28 The Rockefeller University Method for treating pertussis
NZ222902A (en) 1986-12-15 1990-08-28 Yakult Honsha Kk Method for producing galactooligosaccharide
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
SE462134B (sv) 1987-10-22 1990-05-14 Biocarb Ab Livsmedel innehaallande lacto-n-tetraos och foerfarande foer dess framstaellning
CA2095642C (en) 1990-08-02 1999-12-14 Howard C. Krivan Adhesion receptors for pathogenic or opportunistic microorganisms
US5902617A (en) * 1992-05-19 1999-05-11 Pabst; Patrea L. Enzyme supplemented baby formula
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US5922344A (en) 1995-02-10 1999-07-13 Abbott Laboratories Product for prevention of respiratory virus infection and method of use
US5736533A (en) 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
EP1254664A3 (de) 1995-07-10 2004-01-02 Abbott Laboratories Verwendung von unverdaulichen Oligosacchariden zur Vorbeugung und Behandlung von Mittelohrentzündung bei Menschen
DE69506095T2 (de) * 1995-08-04 1999-06-24 Nutricia Nv Diätfasern enthaltende Nahrungszusammensetzung
ID23411A (id) 1997-03-27 2000-04-20 Bristol Myers Squibb Co Penggunaan asam dokosaheksanoat dan asam arakidonat yang meningkatkan pertumbuhan bayi belum cukup bulan
US6045854A (en) 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides
US5906982A (en) 1997-03-31 1999-05-25 Abbott Laboratories Nutritional formulations containing Lacto-N-neoTetraose
US6145670A (en) * 1997-09-22 2000-11-14 Risser; William Bathtub spout with removable filter
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
PT951842E (pt) * 1999-01-20 2003-04-30 Nutricia Nv Formula de alimento adaptada para bebe
EP1062873A1 (de) 1999-12-13 2000-12-27 N.V. Nutricia Verbessertes Säuglingsnährpräparat, Eiweisshydrolysat zur Verwendung in solchem Säuglingsnährpräparat, und Verfahren zur Herstellung solches Hydrolysates
DE10006989A1 (de) 2000-02-16 2001-08-23 Nutricia Nv Antiadhäsive Kohlenhydratmischung
FR2809312B1 (fr) * 2000-05-25 2002-07-12 Gervais Danone Sa Utilisation de l. casei dans des compositions immunostimulantes
AU2000255966B2 (en) * 2000-06-07 2005-03-24 Allergan Sales, Llc Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin
WO2001097817A1 (en) 2000-06-21 2001-12-27 James Zhou Liu Health promoting foods
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
DE10057976B4 (de) 2000-11-22 2005-02-03 Südzucker AG Mannheim/Ochsenfurt Verfahren zur Herstellung von Pektinhydrolyseprodukten
US8227448B2 (en) 2000-12-27 2012-07-24 N.V. Nutricia Nutritional composition with health promoting action containing oligosaccharides
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
DE10147100A1 (de) * 2001-09-25 2003-04-17 Numico Res B V Antiinfektive Kohlenhydrate
WO2003026567A2 (en) 2001-09-27 2003-04-03 St. Jude Children's Research Hospital, Inc. Use of neuraminidase inhibitors to prevent flu associated bacterial infections
US6946451B2 (en) 2002-02-04 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Insulin secretion promoter
ATE428430T1 (de) 2002-06-28 2009-05-15 Glykos Finland Oy Therapeutische zusammensetzungen zur verwendung bei der prophylaxe oder behandlung von durchfall
GB0229015D0 (en) 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
EP1634599A1 (de) * 2004-08-20 2006-03-15 N.V. Nutricia Immunstimulierende Kindernahrung
ES2286558T5 (es) 2004-08-24 2013-10-15 N.V. Nutricia Composición nutritiva que comprende transgalactooligosacáridos indigeribles y sacáridos de galactosa digeribles
US8802650B2 (en) 2010-12-31 2014-08-12 Abbott Laboratories Methods of using human milk oligosaccharides for improving airway respiratory health

Also Published As

Publication number Publication date
CA2576562A1 (en) 2006-03-02
US20080124323A1 (en) 2008-05-29
US20070274983A1 (en) 2007-11-29
PT1629850E (pt) 2007-08-14
ES2704599T3 (es) 2019-03-19
EP1784218A1 (de) 2007-05-16
EP2851090A1 (de) 2015-03-25
RU2385725C2 (ru) 2010-04-10
PL1629850T3 (pl) 2007-09-28
JP2008510803A (ja) 2008-04-10
EP1629850A1 (de) 2006-03-01
AU2005275577A1 (en) 2006-03-02
UA89791C2 (ru) 2010-03-10
US20140296179A1 (en) 2014-10-02
PT2359858T (pt) 2022-11-09
AU2005275577B2 (en) 2011-03-10
ES2286558T5 (es) 2013-10-15
RU2007110813A (ru) 2008-10-10
EP2359858A1 (de) 2011-08-24
PL1629850T5 (pl) 2013-09-30
EP2359858B1 (de) 2022-08-10
AU2005275576A2 (en) 2006-03-02
EP1629850B2 (de) 2013-05-22
DK1629850T4 (da) 2013-07-01
AU2005275576B2 (en) 2011-07-07
US9566291B2 (en) 2017-02-14
JP5142717B2 (ja) 2013-02-13
CN101043904A (zh) 2007-09-26
EP1784222B1 (de) 2018-10-10
CA2577926A1 (en) 2006-03-02
US8277835B2 (en) 2012-10-02
EP1784222A1 (de) 2007-05-16
CA2577926C (en) 2016-08-16
WO2006022543A1 (en) 2006-03-02
WO2006022542A1 (en) 2006-03-02
DE602004006258T3 (de) 2013-08-29
DK1629850T3 (da) 2007-09-10
AU2005275576A1 (en) 2006-03-02
US20130102560A1 (en) 2013-04-25
CA2576562C (en) 2016-03-01
RU2007110822A (ru) 2008-10-10
DE602004006258D1 (de) 2007-06-14
DK2359858T3 (da) 2022-10-31
PL2359858T3 (pl) 2022-12-19
RU2385714C2 (ru) 2010-04-10
EP1629850B1 (de) 2007-05-02
NZ553390A (en) 2009-11-27
CN101094687B (zh) 2011-07-27
BRPI0514536A (pt) 2008-06-17
DE602004006258T2 (de) 2008-01-10
TR201820868T4 (tr) 2019-01-21
ES2286558T3 (es) 2007-12-01
CN101043904B (zh) 2012-04-18
CN101094687A (zh) 2007-12-26
ES2929515T3 (es) 2022-11-29
SG170119A1 (en) 2011-04-29

Similar Documents

Publication Publication Date Title
ATE361101T1 (de) Nahrungszusammensetzung die unverdauliche oligosaccharide enthält
DK1721612T3 (da) Immunmodulerende oligosaccharider
WO2008076915A3 (en) Treatment of pigs with pcv2 antigen
WO2008073464A3 (en) Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
IL158088A0 (en) Remedies for inflammatory bowel diseases
WO2008043424A3 (en) Composition to treat or prevent gastrointestinal infection
UA93201C2 (ru) АНТИТЕЛО, KOTOPOE НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ TGF-b1
WO2009092383A3 (en) Products and methods to prevent infection
WO2004034930A3 (de) Implantat in der harnblase
AU2003202153A1 (en) Composition for preventing or treating mastitis of dairy cattle
EP1670490A4 (de) Verfahren zur hemmung von bakterienkolonisation
WO2005056601A3 (en) Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse?
SE0103695D0 (sv) A novel non-antibiotic strategy against OGIP infections based on a cereal product
ITMI20021881A1 (it) Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.
WO2001058483A3 (en) METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES
ATE420852T1 (de) Verfahren und zusammensetzungen zur behandlung oder prävention von bakteriellen infektionen
TH82887B (th) สารประกอบที่มีฤทธิ์ในการป้องกันและรักษาโรคคอดซิเดียมในไก่
UA3317U (uk) Спосіб лікування гострих кишкових інфекцій

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1629850

Country of ref document: EP